JAGX SEC Filings, Earnings & Splits

Jaguar Health filed a prospectus supplement under Rule 424(b)(3) covering the sale of up to $75,000,000 of common stock, preferred stock, warrants, subscription rights, and units from time to time. The company noted it is no longer subject to the offering limitations of General Instruction I.B.6 of Form S-3.

Jaguar Health stockholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-150, with the exact ratio to be determined by the board within one year. Stockholders also approved several other proposals including warrant repricing, an equity plan increase, and a debt exchange.

Jaguar Health, Inc. filed an EFFECT notice with the SEC, indicating that a registration statement has been declared effective.

Jaguar Health announced that its previously paid special stock dividend of Series R Convertible Preferred Stock automatically converted into common stock on November 2, 2026, at a ratio of five common shares per preferred share, resulting in 13,345,986 common shares outstanding.

Jaguar Health filed an S-3/A registration statement for a $75 million universal shelf offering, including $41.4 million of unsold securities carried forward from a prior shelf and $33.6 million of newly registered securities.

Jaguar Health filed an 8-K supplementing its proxy statement regarding a proposed amendment to its 2014 Stock Incentive Plan. The company also disclosed a special one-time dividend of Series R Preferred Stock that will automatically convert into Common Stock, and a six-fold increase in shares available under the 2014 Plan approved by the Compensation Committee.

Jaguar Health filed an S-3 shelf registration statement, supported by auditor consent from RBSM LLP. The auditor's report includes a going concern explanatory paragraph.

Jaguar Health filed a definitive proxy statement for a special meeting seeking shareholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-150, along with several other proposals including preferred stock exchange, warrant repricing, and an equity plan increase.

Jaguar Health entered into amendments with Uptown Capital and Streeterville Capital to extend the initiation of monthly royalty payments from October 1, 2026 to January 1, 2027, and also extended the maturity date of a secured promissory note with Streeterville to January 1, 2027. Additionally, the company obtained consent from C/M Capital for a preferred stock dividend and authorization of Series R Preferred Stock.

Jaguar Health entered into exchange agreements with Streeterville Capital to issue 481,584 shares of common stock in exchange for a $3.4 million reduction in the outstanding balance of a secured promissory note.